Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

OPN-375 Efficacia e sicurezza negli adolescenti con polipi nasali bilaterali

15 settembre 2026 aggiornato da: Optinose US Inc.

Studio multicentrico a gruppi paralleli controllato con placebo randomizzato in doppio cieco di 16 settimane che valuta l'efficacia e la sicurezza di OPN-375 186 μg due volte al giorno in adolescenti con polipi nasali bilaterali seguiti da una fase di trattamento in aperto di 12 settimane

This is a 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. The total planned number of subjects is approximately 72 adolescents (12-17 years of age) who will be randomly assigned to receive 1 of 2 study treatments using a 2:1 ratio (OPN-375 186 μg: Placebo). For the PK sub-study, up to 14 subjects will be enrolled to obtain 10 completers.

Panoramica dello studio

Stato

Completato

Intervento / Trattamento

Descrizione dettagliata

The primary objective of this study is to evaluate the efficacy of intranasal administration of OPN-375 186 μg Twice a Day (BID) versus placebo in adolescents with bilateral nasal polyposis and nasal congestion by analyzing the reduction of nasal congestion/obstruction symptoms at the end of Week 4 measured by the 7-day average instantaneous morning diary symptom scores and the reduction in total polyp grade at Week 16 as determined by a nasal polyp grading scale score measured using a 0 to 6 point severity grading scale.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

40

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Buenos Aires, Argentina, C1411ABE
        • Fundacion CIDEA
      • Buenos Aires, Argentina, C1425BEN
        • InAER - Investigaciones en Alergia y Enfermedades Respiratorias
      • Buenos Aires, Argentina, C1180AAX
        • Sanatorio Guemes
      • Corrientes, Argentina, W3400AVV
        • Instituto de Asma Alergia y Enfermedades Respiratoria (IAAER)
      • Mendoza, Argentina, M5500CCG
        • Centro Medico INSARES
    • Córdoba Province
      • Río Cuarto, Córdoba Province, Argentina, X5008AEV
        • Instituto Medico Rio Cuarto
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, S2000DEJ
        • Instituto Medico de la Fundacion de Estudios Clinicos - Consultorios Integrados Rosario
      • Rosario, Santa Fe Province, Argentina, S200DBS
        • Centro de Investigaciones Clinicas - Instituto de la Salud Rosario
    • Tucumán Province
      • San Miguel de Tucumán, Tucumán Province, Argentina, T4000IHE
        • Clinica Mayo, UMCB
    • Arizona
      • Gilbert, Arizona, Stati Uniti, 85234
        • San Tan Allergy & Asthma
    • California
      • Bakersfield, California, Stati Uniti, 93301
        • Kern Research
      • Fresno, California, Stati Uniti, 93720
        • Central California Clinical Research
      • Los Angeles, California, Stati Uniti, 90027
        • Children's Hospital of Los Angeles
      • Los Angeles, California, Stati Uniti, 90006
        • Sensa Health
      • Orange, California, Stati Uniti, 92868
        • Children's Hospital of Orange County
      • Redwood City, California, Stati Uniti, 94063
        • Allergy and Asthma Consultants
      • Roseville, California, Stati Uniti, 95661
        • Sacramento ENT
      • San Diego, California, Stati Uniti, 92123
        • Rady Children's Hospital San Diego
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • Children's Hospital Colorado
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
        • Children's Healthcare of Atlanta
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60657
        • Chicago ENT
    • Kentucky
      • Louisville, Kentucky, Stati Uniti, 40205
        • Kentuckiana ENT
    • New York
      • Rochester, New York, Stati Uniti, 14642
        • University of Rochester
    • North Carolina
      • Charlotte, North Carolina, Stati Uniti, 28204
        • Allergy Asthma & Immunology Research Institute
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti, 73120
        • Allergy, Asthma & Clinical Research Center
      • Tulsa, Oklahoma, Stati Uniti, 74136
        • Vital Prospects Clinical Research Institute, P.C.
    • South Carolina
      • Orangeburg, South Carolina, Stati Uniti, 29118
        • Carolina ENT
    • Texas
      • San Antonio, Texas, Stati Uniti, 78229
        • STAAMP Research
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84132
        • University of Utah
    • Virginia
      • Norfolk, Virginia, Stati Uniti, 23507
        • Eastern Virginia Medical School - Otolaryngology
    • Washington
      • Spokane Valley, Washington, Stati Uniti, 99216
        • Spokane ENT

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 12 anni a 17 anni (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Male or female subjects aged 12 to 17 years, inclusive, at time of Visit 1 (Screening).

  2. Female subjects, if sexually active, must,

    1. be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and throughout the study, or
    2. be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), or
    3. be abstinent.
  3. All female subjects not documented to be infertile (e.g., infertility due to congenital abnormality or surgical sterilization) must have a negative serum or urine beta-human chorionic gonadotropin (hCG) at Visit 1 (Screening) and a negative urine pregnancy test at the Visit 2 (Day 1/Randomization/Baseline).

  4. Must have bilateral nasal polyposis with a grade of 1 to 3 in each of the nasal cavities as determined by a nasal polyp grading scale score measured by nasoendoscopy at Visit 1 (Screening).

  5. Must report at least mild symptoms of nasal congestion/obstruction as demonstrated by an average morning nasal congestion/obstruction score of at least 1.0 over a 7 day period during the single-blind run-in period. (Subjects not meeting this inclusion criterion may be re-screened once after at least 4 weeks.)

  6. Subjects with comorbid asthma must be stable, defined as no exacerbations (e.g., no emergency room visits, hospitalization, or oral or parenteral steroid use) within the 3 months before Visit 1 (Screening). Subjects who received inhaled corticosteroids are required to be on no more than a moderate dosage regimen as defined by 2015 Global Initiative for Asthma Guidelines (GINA) for 1 month before Visit 1 (Screening) and to be expected to remain on it throughout the study (GINA 2015). Subjects receiving inhaled fluticasone alone or in combination may not participate in the PK sub-study.

  7. Must be able to cease treatment with intranasal medications including, but not limited to, intranasal oxymetazoline or any other decongestants, intranasal antihistamines, intranasal steroids, intranasal sodium cromolyn, nasal atropine, nasal ipratropium bromide, inhaled corticosteroids (except permitted doses listed above for asthma) at Visit 1 (Screening). [Note: intranasal antibiotics and saline are permissible]

  8. If taking oral antihistamines, must be on a stable regimen for at least 2 weeks prior to Visit 1 (Screening), and agree to not change the dose of these medications until after Visit 3 (Week 4) of the study.

  9. Subjects (with assistance from parent or legal guardian if needed) must demonstrate the ability to complete the daily diary during the run-in period to be eligible for randomization.

  10. Must demonstrate correct use of the demo EDS.

  11. Must be capable, in the opinion of the investigator, of providing assent and the appropriate parent(s) or guardian must provide an informed consent to participate in the study.

Exclusion Criteria:

  1. Pregnancy or lactation
  2. Has a history of cystic fibrosis
  3. Have used XHANCE (fluticasone propionate) nasal spray within the past 2 months
  4. Inability to achieve bilateral nasal airflow for any reason, including nasal septum deviation
  5. Inability to examine both nasal cavities for any reason, including severe nasal septum deviation
  6. Have known history of nasal septum erosion, ulceration or perforation, or evidence of such lesion on Visit 1 (Screening) nasal examination/nasoendoscopy
  7. Other significant nasal pathology or abnormal anatomy
  8. Has had any episode of epistaxis with frank bleeding in the 3 months before Visit 1 (Screening)
  9. History of more than 5 sinus or nasal surgeries for either nasal polyps or nasal/sinus inflammation (lifetime)
  10. Have had any surgery on the nasal septum
  11. History of sinus or nasal surgery within 6 months before Visit 1 (Screening)
  12. History of any surgical procedure that prevents the ability to accurately diagnose or grade polyps
  13. Current, ongoing rhinitis medicamentosa (rebound rhinitis)
  14. Have significant oral structural abnormalities (e.g., a cleft palate)
  15. History of Churg-Strauss syndrome or dyskinetic ciliary syndromes
  16. Purulent nasal infection (recent fever or symptoms of lethargy), acute sinusitis, or upper respiratory tract infection within 2 weeks before Visit 1 (Screening). Potential subjects presenting with one of these infections may be rescreened after 4 weeks.
  17. Have an allergy, hypersensitivity, or contraindication to corticosteroids or steroids
  18. Have a hypersensitivity to any excipients in the study drug
  19. Exposure to any glucocorticoid treatment with potential for systemic effects (e.g., oral or parenteral steroids, high dose topical steroids) within 1 month before Visit 1 (Screening); except as noted in inclusion criteria for subjects with comorbid asthma
  20. Have received mepolizumab (Nucala®), reslizumab (Cinquair®), dupilumab (Dupixent®), omalizumab (Xolair®), or benralizumab (Fasenra™) within 6 months of Visit 1
  21. Have nasal or oral candidiasis
  22. Have taken a potent CYP3A4-inhibitor within 14 days before Visit 1 (Screening)
  23. Any serious or unstable concurrent disease, psychiatric disorder, or any significant concomitant medical condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject's participation or compliance in the study, or pose a specific risk to the subject due to study participation
  24. History or current diagnosis of any form of glaucoma or ocular hypertension (i.e., >21 mm Hg)
  25. History of intraocular pressure elevation on any form of steroid therapy
  26. Current diagnosis of the presence (in either eye) of a cataract of Grade 1 or greater as defined on the Eye Examination Worksheet OR, less than a Grade 1 cataract with associated visual impairment
  27. A recent (within 1 year of Visit 1 [Screening]) history of drug or alcohol abuse or dependence
  28. Positive urine drug screen at screening visit for stimulants, opioids, or cocaine
  29. Have participated in an investigational drug clinical trial within 30 days of Visit 1 (Screening)
  30. Parents, guardian or caregivers of the subject who are employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: OPN-375 186 μg BID

Double-Blind Treatment Phase: OPN-375 186 μg BID x 16 weeks

Open-Label Extension Phase: OPN-375 186 μg BID x 12 weeks

OPN-375, BID

Comparatore placebo: Placebo

Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks

OPN-375, BID

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in nasal congestion/obstruction symptoms (mild, moderate, severe) at the end of Week 4
Lasso di tempo: 4 Weeks

Change in nasal congestion/obstruction symptoms at the end of Week 4 measured by the 7-day average instantaneous morning (AM) diary symptom scores (ADS7-IA). The nasal symptom scale is what is used to score the nasal congestion/obstruction score, which is recorded in the diary. Nasal symptom scale is graded on a scale of 0=no symptom, 1=mild symptom, 2=moderate symptom, 3=severe symptom.

4 Weeks
Mean change from baseline at Week 16 in total polyp grade
Lasso di tempo: 16 Weeks

Change in total polyp grade (sum of scores from both nasal cavities) at Week 16 as determined by a nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

16 Weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in bilateral polyp grade over time
Lasso di tempo: 16 Weeks

nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

16 Weeks
Percentage of subjects with a ≥1 point improvement in polyp grade
Lasso di tempo: 16 Weeks

nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

16 Weeks
Percentage of subject with a grade of 0 on at least one side of the nose
Lasso di tempo: 16 Weeks

nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

16 Weeks
Change in diary symptom scores for the symptoms of nasal congestion/obstruction, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)
Lasso di tempo: 16 Weeks

The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)

16 Weeks
Change in diary symptom scores for the symptoms of rhinorrhea, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)
Lasso di tempo: 16 Weeks

The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)

16 Weeks
Change in diary symptom scores for the symptoms of facial pain or pressure, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)
Lasso di tempo: 16 Weeks

The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)

16 Weeks
Change in diary symptom scores for the sense of smell, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)
Lasso di tempo: 16 Weeks

Sense of smell will be scored on a scale from 0 (normal) to 3 (absent, no sense of smell)

16 Weeks
The proportions of subjects who have reductions in the AM and PM, instantaneous and reflective, average nasal congestion/obstruction symptom scores by 0.5 or more points from baseline to the end of the double-blind treatment phase
Lasso di tempo: 16 Weeks

The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)

16 Weeks
Subjects will assess their global impression of change since starting the study drug using the PGIC scale
Lasso di tempo: 16 Weeks

Subject global impression of change will be assessed using a subject-completed PGIC scale, with a single question rated from 1=very much improved to 7=very much worse

16 Weeks
Subjects will assess their change in quality of life since starting the study drug using the quality of life questionnaire (SN-5).
Lasso di tempo: 16 Weeks

Quality of life assessment using the SN-5 Questionnaire, a subject/parent-completed questionnaire that consists of 5 specific symptoms-related questions (answered on a 7-point Likert scale on the frequency of symptoms, 1=none of the time, 7=all of the time), and 1 general overall quality of life question (answered on a visual analog scale from 0 to 10, worst to best).

16 Weeks
Proportion of subjects eligible for surgical intervention (independent of actual surgery performed)
Lasso di tempo: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

The assessment criteria are as follows:

  • Subject has had moderate symptoms of congestion from nasal polyposis for at least 3 months.
  • Subject continues to suffer from at least moderate symptoms despite use of topical steroids at conventional doses for at least 6 weeks.
  • Subject continues to suffer from at least moderate symptoms despite use (or previous use) of saline lavage for at least 6 weeks.
  • Subject has endoscopically visualized bilateral nasal polyposis of at least moderate severity (nasal polyp grading score > 2 in at least 1 nostril). Also assess each subject's eligibility for surgery based on specific of criteria (see Section 12) independent of whether the subject actually undergoes surgery.
Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Valutazione della sicurezza dalla raccolta di informazioni per l'uso concomitante di farmaci
Lasso di tempo: 16 settimane
16 settimane
Assessment of safety from physical examination-measuring weight
Lasso di tempo: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Assessment of safety from physical examination-weight measured in kg or lb

Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety from physical examination-measuring height
Lasso di tempo: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Assessment of safety from physical examination-height measured in cm or in

Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety by recording the severity of AEs
Lasso di tempo: 16 Weeks

Assessment of safety by measuring severity of AEs using scale with 1=mild, 2=moderate, 3=severe

16 Weeks
Assessment of safety by nasal examination
Lasso di tempo: 16 Weeks

Assessed in nasal examination worksheet which includes recording the presence of any epistaxis, septal erosion/perforation, ulceration/erosion of area other than septum. If present, the nostril location is also recorded, along with severity, and if there is any relation to an injury or trauma

16 Weeks
Assessment of safety by ocular examination-visual acuity
Lasso di tempo: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Assessment of safety by performing visual acuity test assessment using eye chart. Separate recording for each eye in the form of a fraction, 20/...

Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety by ocular examination-Intraocular Pressure
Lasso di tempo: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Assessment of safety by averaging intraocular pressure measurement of 2 or 3 measurements to determine if it is >21mmHg

Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety by ocular examination-Cataract Evaluation
Lasso di tempo: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Cataracts should be again assessed present or absent, If cataract is diagnosed, cataract type per localization should be specified and cataract should be graded 1=mild, 2=moderate, 3=pronounced, 4=severe

Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety measuring vital signs (blood pressure)
Lasso di tempo: 16 Weeks

Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)

16 Weeks
Assessment of safety measuring vital signs (pulse)
Lasso di tempo: 16 Weeks

measure pulse in beats per minute (bpm)

16 Weeks
Assessment of pharmacokinetics - AUC(0-t) (pg*hr/mL)
Lasso di tempo: 8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [AUC(0-t) (pg*hr/mL) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - AUC(0-∞) (pg*hr/mL)
Lasso di tempo: 8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [AUC(0-∞) (pg*hr/mL) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - AUCex (%)
Lasso di tempo: 8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [AUCex (%) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - Cmax (pg/mL)
Lasso di tempo: 8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [Cmax (pg/mL) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - tmax (h)
Lasso di tempo: 8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [tmax (h) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - t1/2 (h)
Lasso di tempo: 8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [t1/2 (h) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Cattedra di studio: Amy Manley, Paratek Pharma

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

31 dicembre 2018

Completamento primario (Effettivo)

31 marzo 2026

Completamento dello studio (Effettivo)

11 giugno 2026

Date di iscrizione allo studio

Primo inviato

23 ottobre 2018

Primo inviato che soddisfa i criteri di controllo qualità

16 novembre 2018

Primo Inserito (Effettivo)

20 novembre 2018

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

15 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • OPN-FLU-NP-3103

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi